(lp0
S'Albireo Pharma Inc. ALBO  Wall Street Journal - Feb 1, 2001 News Albireo Pharma Inc.ALBO. Significant News Only. 04/10/17; Press Release. Albireo to Host KOL Meeting on Rare Pediatric Liver Diseases on April 12.'
p1
aS'19.62 MarketWatch - Nov 9, 2016 Join TD Ameritrade dblc_tracking Find a Broker. Albireo Pharma Inc. Watchlist CreateALBOAlert. Closed. Last Updated: Apr 17, 2017 4:00 p.m.. $ 19.62. -1.20 -5.76%. Previous Close. $20.8200. Created with Highstock 2.1.8 10am 11am 12pm 1pm 2pm 3pm&nbsp;...'
p2
aS'Equity Watch: Albireo Pharma, Inc.  Benton Bulletin - 18 hours ago Albireo Pharma, Inc.  presently has a Piotroski F-Score of 4. The goal of the F-Score is to help locate companies with strengthening balance sheets, and to weed out poor performers.'
p3
aS"Albireo Completes Transaction with Biodel to Create Publicly Traded Company ... GlobeNewswire  - Nov 3, 2016 BOSTON, Nov. 03, 2016  -- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators through its operating subsidiary, today announced the completion of the share exchange&nbsp;...Nine stories you may have missed Thursday from the world of business - The Boston GlobeBoston's newest public company, Albireo, aims to treat kids' liver diseases - Boston Business Journal"
p4
aS'BRIEF-Albireo Pharma Inc says filed for mixed shelf offering of up to $100 mln Reuters - Dec 22, 2016 TOKYO, March 21 Asian shares clung to their 15-month highs on Tuesday while the dollar and U.S. bond yields were on the back foot on the prospects of a less-hawkish Federal Reserve policy trajectory.'
p5
aS"Trader Alert: Unusual Volume Spotted in Albireo Pharma, Inc.  The Herald - 9 hours ago Investors are on alert as Albireo Pharma, Inc. 's stock is experiencing unusual volume during today's trading."
p6
aS"Albireo Pharma  CEO Ron Cooper on Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Mar 14, 2017 Good morning, ladies and gentlemen, and thank you for joining us for Albireo's financial results conference call to review results for 2016.Albireo Reports 2016 Financial Results - GlobeNewswire "
p7
aS'Albireo Pharma  Says A4250 Data Selected for Late Breaker Presentation ... StreetInsider.com - Apr 5, 2017 Albireo Pharma, Inc. , a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that clinical data from the ongoing Phase 2 study of its lead product candidate A4250 in children with&nbsp;...Zacks Investment Research Upgrades Albireo Pharma, Inc.  to Hold - Sports PerspectivesAlbireo Pharma, Inc.  Given $40.00 Average Price Target by Brokerages - Chaffey Breeze'
p8
aS"Top Sizzling Mover of Thursday: Albireo Pharma, Inc.'s  stock price ... WsNews 4investors - 20 hours ago Albireo Pharma, Inc.  stock price tumbled -0.86% to finalize at $20.82 throughout previous buying and selling session."
p9
aS"Is Now the Time to Buy Albireo Pharma, Inc. ? Analyst's Take Midway Monitor - 17 hours ago Research brokerage firms on Wall Street are offering a consensus Buy rating on shares of Albireo Pharma, Inc. ."
p10
a.